ArticleMedicine2026
The association between agranulocytosis and 30-day mortality in patients with hematological disorders and bloodstream infections: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Agranulocytosis and bloodstream infections (BSIs) are common complications in patients with hematological disorders and they are life-threatening. This study aims to explore the association between agranulocytosis and 30-day mortality in individuals with hematological disorders and BSIs. In this retrospective cohort study, neutrophil levels were measured in patients presenting with fever and diagnosed with a hematological disorder at Tongde Hospital of Zhejiang Province between March 2018 and August 2023. The primary outcome was all-cause 30-day mortality. Multivariate Cox proportional hazard models were used to identify factors associated with survival among patients with hematological disorders and BSIs. Survival outcomes between agranulocytosis (neutrophils < 0.5 × 109/L) and non-agranulocytosis (neutrophils ≥ 0.5 × 109/L) were compared via the Kaplan-Meier method. Subgroup analyses were conducted, stratified by relevant effect covariates. The study included 113 (56.8%) males and 86 (43.2%) females, with a median age of 57.4 years. The overall 30-day mortality rate was 33.7% (67/199), with mortality rate of 26.1% (24/92) in the non-agranulocytosis group and 40.2% (43/107) in the agranulocytosis group (P = .036). After adjusting for potential confounders, a significant association between a 2% increase in the 30-day mortality rate and a 0.1 × 109/L decrease in neutrophil levels was observed (95% confidence interval [CI]: 1.00-1.03, P = .006). Furthermore, agranulocytosis was associated with a 95% increase in 30-day mortality compared to non-agranulocytosis (95% CI: 1.10-3.46, P = .023). The findings from the subgroup and stratified analyses were consistent and robust. Agranulocytosis was positively associated with all-cause 30-day mortality in patients with hematological disorders and BSIs. It served as a significant early prognostic indicator for hematological patients who develop BSIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.